Comparative Pharmacology
Head-to-head clinical analysis: ANDROID 10 versus TESTRED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID 10 versus TESTRED.
ANDROID 10 vs TESTRED
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.
Testosterone is an androgen receptor agonist, promoting development of male secondary sexual characteristics and anabolic effects.
Male hypogonadism (primary and hypogonadotropic)Delayed puberty in malesOff-label: Androgen replacement in transgender men (masculinizing hormone therapy)
Testosterone replacement therapy for male hypogonadismDelayed puberty in malesMetastatic breast cancer in women (limited use)
Testosterone undecanoate 750 mg (3 mL) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.
Testosterone enanthate 200 mg intramuscularly every 2 weeks.
None Documented
None Documented
8 hours; clinical context: steady-state achieved in 2-3 days, dosing interval 8-12 hours.
Terminal elimination half-life for testosterone is 2-4 hours; testosterone enanthate has a half-life of 4-5 days due to slow release from the oily depot. Clinical context: shorter half-life requires more frequent dosing for stable serum levels.
Hepatic metabolism via CYP3A4; undergoes extensive first-pass metabolism; metabolites primarily excreted renally.
Hepatic via CYP3A4 and other CYP enzymes; metabolites include androsterone and etiocholanolone.
Renal: 90% as glucuronide and sulfate conjugates, 6% as unchanged drug; fecal: 4%.
Approximately 90% of administered testosterone is excreted in urine as glucuronide and sulfate conjugates of testosterone and its metabolites (androsterone, etiocholanolone). About 6% is excreted in feces via bile. Unchanged testosterone excretion is negligible (<1%).
97-99% bound primarily to sex hormone-binding globulin (SHBG) and albumin.
Approximately 98-99% bound to sex hormone-binding globulin (SHBG, ~40%) and albumin (~60%) in adult males. Free testosterone fraction is ~1-2%.
0.5-1.0 L/kg; indicates extensive distribution into tissues and organs.
Volume of distribution for testosterone is approximately 0.5-1.0 L/kg, indicating distribution into total body water and tissues (e.g., muscle, prostate). Clinical meaning: wide distribution, tissue binding important for effects.
Oral: low (variable, ~5-20% due to first-pass metabolism); intramuscular: 100%.
Oral testosterone: low and variable (<10%) due to extensive first-pass metabolism; methyltestosterone: ~40-60% (resistant to hepatic metabolism). Intramuscular (enanthate): 100% (systemic). Transdermal: ~10-14% (patch), 6-12% (gel). Buccal: ~80-90%.
No specific dose adjustment required for renal impairment; monitor serum testosterone levels and clinical response. For severe renal impairment (GFR <30 mL/min), consider increased monitoring due to potential fluid retention.
No specific dose adjustment recommended for renal impairment; use with caution in severe renal impairment due to potential fluid retention.
Contraindicated in patients with severe hepatic dysfunction (Child-Pugh class C). For mild to moderate impairment (Child-Pugh class A or B), use with caution and consider dose reduction; monitor liver function tests regularly.
Contraindicated in patients with Child-Pugh class B or C cirrhosis. For Child-Pugh class A, use with caution and monitor liver function; no specific dose adjustment provided.
Not recommended for use in children; safety and efficacy not established. For delayed puberty in adolescent males: testosterone enanthate 50-200 mg intramuscularly every 2-4 weeks, titrated to response, with monitoring of bone age.
Not recommended for use in children; safety and efficacy not established.
Start at low end of dosing range (e.g., testosterone cypionate 50 mg intramuscularly every 4 weeks or gel 25 mg daily) due to potential increased sensitivity and risk of prostatic hypertrophy or cardiovascular events. Monitor serum testosterone, hematocrit, and prostate-specific antigen (PSA).
Use with caution in elderly patients due to increased risk of prostatic hypertrophy and cardiovascular events; monitor prostate-specific antigen and hematocrit regularly.
None
WARNING: VIRILIZATION IN WOMEN, PRECOCIOUS PUBERTY IN CHILDREN, AND HEPATOTOXICITY. Testosterone has been associated with hepatic adenomas and hepatocellular carcinoma.
Risk of hepatotoxicity; use with caution in patients with liver disease. Monitor liver function, lipid profile, and prostate-specific antigen (PSA). May cause fluid retention, gynecomastia, priapism, and sleep apnea. Not for use in women who are pregnant or breastfeeding. May accelerate growth of prostate cancer and benign prostatic hyperplasia. Androgenic effects may cause virilization in women.
Monitor for polycythemia, sleep apnea, cardiovascular risk, hypercalcemia in breast cancer patients, and potential for secondary exposure (virilization in children).
Men with carcinoma of the prostate or breast; history of hypersensitivity to testosterone or any component; women who are pregnant or may become pregnant (risk of fetal harm); patients with severe hepatic or cardiac disease.
Known or suspected prostate cancer, male breast cancer, severe hepatic impairment, pregnancy, lactation.
Data Pending Review
Data Pending Review
No known food interactions. However, methyltestosterone can increase appetite and cause weight gain; a balanced diet is recommended.
No significant food interactions. Avoid excessive alcohol consumption as it may increase risk of hepatotoxicity. Grapefruit juice does not interact significantly. Maintain a balanced diet to support overall health during androgen therapy.
Android 10 is a combination of methyltestosterone and ethinyl estradiol. Methyltestosterone is an androgen; exposure during pregnancy, particularly during the first trimester, can cause virilization of the female fetus. Ethinyl estradiol is contraindicated in pregnancy due to risk of fetal harm. Use is contraindicated in all trimesters.
Pregnancy Category X. Testosterone can cause virilization of female fetus, including clitoromegaly, labial fusion, and urogenital sinus abnormalities. Risk is highest during first trimester when organogenesis occurs. Contraindicated in pregnancy.
Methyltestosterone and ethinyl estradiol are excreted in breast milk. Methyltestosterone may cause virilization in female infants. Ethinyl estradiol may reduce milk production and quality. M/P ratio not available. Breastfeeding is contraindicated.
Testosterone is excreted into breast milk. M/P ratio not established. Potential adverse effects include virilization in female infants and growth acceleration. Use during breastfeeding is contraindicated.
Contraindicated in pregnancy; no dosing adjustments apply. If inadvertent use occurs, discontinue immediately.
No dose adjustments applicable as Testosterone is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy include increased volume of distribution and altered protein binding, but use is not recommended.
Category C
Category C
Android 10 is a brand name for methyltestosterone, an androgen and anabolic steroid. Use is restricted to replacement therapy in males with hypogonadism or delayed puberty due to androgen deficiency. Monitor liver function due to risk of peliosis hepatis and hepatocellular carcinoma. Contraindicated in males with breast or prostate cancer. Can cause erythrocytosis; monitor hematocrit. Discontinue if signs of virilization in women or priapism in men. Use caution in elderly due to increased risk of prostatic hypertrophy.
Monitor for signs of virilization in women and precocious puberty in children. Measure serum testosterone levels periodically to ensure therapeutic range and avoid supraphysiologic levels. Assess liver function tests, lipid profile, and hematocrit/hemoglobin at baseline and periodically. Use with caution in patients with known or suspected prostate cancer or breast cancer. Avoid in men with severe lower urinary tract symptoms due to benign prostatic hyperplasia. Intramuscular injections should be given deep into the gluteal muscle to minimize injection site reactions.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.Report signs of liver problems: yellowing of skin or eyes, dark urine, light-colored stools, abdominal pain.Notify your doctor if you experience swelling of ankles or feet, trouble breathing, or persistent erections lasting more than 4 hours.May cause aggressive behavior, mood swings, or depression; contact your doctor if these occur.Do not take if you are pregnant or breastfeeding.Keep all appointments for blood tests and liver function monitoring.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.Report any signs of virilization (e.g., deepened voice, facial hair growth, acne) or unusual changes in mood, sleep, or libido.For transdermal formulations, apply to clean, dry skin on the back, abdomen, or thighs; rotate sites to avoid irritation.Do not use in women who are or may become pregnant; can cause harm to the fetus.Keep out of reach of children; store at room temperature away from moisture and heat.Inform your doctor of all other medications, including over-the-counter, vitamins, and herbal supplements.Regular blood tests are required to monitor safety and effectiveness.